Hugh Alexander Ilyine

ProFactor Pharma Ltd. develops and supplies recombinant blood factors for the treatment of haemophilia. The firm commercialise and supply recombinant blood factors for the treatment of haemophilia to a undersupplied world market, starting with recombinant human Factor VIII (rhFVIII). The company was founded by Richard John Cruse, Ian Garner, Bruce Vernon, Hugh Ilyine and John H. McVey in 2009 and is headquartered in Midlothian, the United Kingdom.

Destina Genomics Ltd. is engaged in development of molecular diagnostic products. Its products include pipeline assay kits and liverace. The company was founded by Hugh Llyine, Juan J. Diaz-Mochon and Mark Bradley in 2011 and is headquartered in Edinburgh, the United Kingdom.

ProFactor Pharma Ltd. develops and supplies recombinant blood factors for the treatment of haemophilia. The firm commercialise and supply recombinant blood factors for the treatment of haemophilia to a undersupplied world market, starting with recombinant human Factor VIII (rhFVIII). The company was founded by Richard John Cruse, Ian Garner, Bruce Vernon, Hugh Ilyine and John H. McVey in 2009 and is headquartered in Midlothian, the United Kingdom.

ProFactor Pharma Ltd. develops and supplies recombinant blood factors for the treatment of haemophilia. The firm commercialise and supply recombinant blood factors for the treatment of haemophilia to a undersupplied world market, starting with recombinant human Factor VIII (rhFVIII). The company was founded by Richard John Cruse, Ian Garner, Bruce Vernon, Hugh Ilyine and John H. McVey in 2009 and is headquartered in Midlothian, the United Kingdom.

Destina Genomics Ltd. is engaged in development of molecular diagnostic products. Its products include pipeline assay kits and liverace. The company was founded by Hugh Llyine, Juan J. Diaz-Mochon and Mark Bradley in 2011 and is headquartered in Edinburgh, the United Kingdom.